04/01/2026
There are lakes, literally lakes of poisonous waste being created because of our broken relationship to food.
These drugs may reduce weight —
but their manufacturing footprint is chemically extreme.
The uncomfortable truth
These drugs are marketed as healthcare breakthroughs —
yet rely on chemical processes that damage fertility, threaten workers, and pollute ecosystems.
This isn’t anti-medicine.
It’s pro-accountability.
If a product improves metabolic health
but degrades environmental & reproductive health —
is that really “progress”?
• GLP-1 drugs use large volumes of toxic organic solvents
• ~14,000 kg of hazardous waste produced per 1 kg of active drug
One key solvent: DMF (dimethylformamide)
• Classified as reprotoxic (damages fertility)
• Absorbed through skin AND inhalation
• Linked to: – Reduced s***m quality
– Menstrual disruption
– Miscarriage
– Foetal toxicity
EU exposure limits (2023):
• Max airborne exposure: 6 mg/m³
• Max skin absorption: 1.1 mg per kg body weigh
These are exceptionally low thresholds — indicating high biological risk
Worker health concerns
• Waste flagged specifically for reproductive toxicity
• Cannot be safely handled without strict containment
• Increasing regulatory concern for: – Lab technicians
– Factory workers
– Chemical handlers
⚠️ Several solvents used are already restricted
⚠️ Others are under review for future bans
• Waste is too toxic for landfill
• Must be incinerated (high-energy, polluting)
• Creates: – Solvent-contaminated liquid waste
– Persistent chemical residues
– Long-term environmental burden
• Manufacturing is energy-intensive
• Scaling production = exponentially more waste
📈 Why this problem is accelerating
• Global GLP-1 market projected to reach $150 BILLION by 2035
• New factories being built by companies like Novo Nordisk
• Pill versions = more users, same toxic process